Natixis Advisors LLC Has $3.29 Million Stock Holdings in Balchem Co. (NASDAQ:BCPC)

Natixis Advisors LLC grew its holdings in Balchem Co. (NASDAQ:BCPC) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,344 shares of the basic materials company’s stock after acquiring an additional 375 shares during the quarter. Natixis Advisors LLC’s holdings in Balchem were worth $3,286,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. increased its stake in Balchem by 1.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 3,926 shares of the basic materials company’s stock worth $604,000 after acquiring an additional 59 shares during the period. GAMMA Investing LLC increased its position in shares of Balchem by 18.0% in the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after purchasing an additional 72 shares during the period. Pitcairn Co. raised its stake in Balchem by 3.6% in the first quarter. Pitcairn Co. now owns 3,315 shares of the basic materials company’s stock valued at $514,000 after purchasing an additional 115 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Balchem by 2.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,278 shares of the basic materials company’s stock worth $1,120,000 after purchasing an additional 177 shares during the period. Finally, Annex Advisory Services LLC grew its stake in Balchem by 4.8% during the first quarter. Annex Advisory Services LLC now owns 3,967 shares of the basic materials company’s stock worth $615,000 after buying an additional 182 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

Insider Buying and Selling

In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the transaction, the senior vice president now directly owns 8,540 shares in the company, valued at approximately $1,537,627. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.25% of the stock is owned by corporate insiders.

Balchem Price Performance

Shares of BCPC stock opened at $168.63 on Monday. The business has a fifty day simple moving average of $169.42 and a 200 day simple moving average of $158.22. The company has a market cap of $5.47 billion, a P/E ratio of 47.64, a P/E/G ratio of 5.59 and a beta of 0.65. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26. Balchem Co. has a twelve month low of $110.74 and a twelve month high of $186.03.

Balchem (NASDAQ:BCPC) last issued its earnings results on Friday, July 26th. The basic materials company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. Balchem had a return on equity of 10.94% and a net margin of 12.52%. The firm had revenue of $234.08 million during the quarter, compared to the consensus estimate of $241.26 million. On average, sell-side analysts forecast that Balchem Co. will post 3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a research report on Monday, July 29th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.